Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

INTRODUCTION: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with h...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Epidemiol
Autori principali: Horváth-Puhó, Erzsébet, Suttorp, Marit M, Frederiksen, Henrik, Hoekstra, Tiny, Dekkers, Olaf M, Pedersen, Lars, Cannegieter, Suzanne C, Dekker, Friedo W, Sørensen, Henrik Toft
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167129/
https://ncbi.nlm.nih.gov/pubmed/30310329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S172306
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi